Online Program Home
My Program

Abstract Details

Activity Number: 110 - Assessing Treatment Effects for Life History Processes
Type: Topic Contributed
Date/Time: Monday, July 30, 2018 : 8:30 AM to 10:20 AM
Sponsor: Biopharmaceutical Section
Abstract #328939 Presentation
Title: Symptom Trials Vs Morbidity/Mortality Trials: Are Different Estimands Required?
Author(s): Steven Snapinn*
Companies: Amgen, Inc.
Keywords: Clinical Trials; Endpoint; Intercurrent Event

One imperfect but convenient way of classifying clinical trials is on the basis of the type of primary endpoint being evaluated. Two broad classes of endpoints include symptoms, such as pain relief or glucose control, and morbidity/mortality, such as a major adverse cardiovascular event or overall survival. In the case of symptom trials the occurrence of intercurrent events, such as the use of rescue medication, often calls into question the strict application of the intention-to-treat (ITT) estimand. In the case of morbidity/mortality trials, on the other hand, even though such intercurrent events can occur, tradition often calls for strict ITT. In this presentation I will discuss the rationale for this distinction, and argue that the justification for an ITT estimand is the same in both situations.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2018 program